{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"Complete response, partial response or minimal response based on serum M-protein assessments. Complete and partial responses are as defined for the primary outcome measure. Minimal response is defined as 25 to 49% reduction from baseline in serum M-protein level, maintained for a minimum of 6 weeks.","groups":[{"description":"Open-label denosumab 120 mg by subcutaneous injection on day 1 of each 28-day cycle with additional loading doses on days 8 and 15 of cycle 1 in participants with plateau-phase multiple myeloma","id":"OG000","title":"Denosumab 120 mg Q4W - Plateau-Phase"},{"description":"Open-label denosumab 120 mg by subcutaneous injection on day 1 of each 28-day cycle with additional loading doses on days 8 and 15 of cycle 1 in participants with relapsed multiple myeloma","id":"OG001","title":"Denosumab 120 mg Q4W - Relapsed"}],"paramType":"NUMBER","populationDescription":"All participants who completed the first cycle of treatment with denosumab","reportingStatus":"POSTED","timeFrame":"Up to 18 months","title":"Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only","type":"SECONDARY","unitOfMeasure":"Participants"}